MX386750B - MARCADORES DE METILACIÓN Y DE miARN PARA LA DETECCIÓN DE CÁNCER. - Google Patents

MARCADORES DE METILACIÓN Y DE miARN PARA LA DETECCIÓN DE CÁNCER.

Info

Publication number
MX386750B
MX386750B MX2017010836A MX2017010836A MX386750B MX 386750 B MX386750 B MX 386750B MX 2017010836 A MX2017010836 A MX 2017010836A MX 2017010836 A MX2017010836 A MX 2017010836A MX 386750 B MX386750 B MX 386750B
Authority
MX
Mexico
Prior art keywords
methylation
cancer detection
mirna markers
marker
cancer
Prior art date
Application number
MX2017010836A
Other languages
English (en)
Other versions
MX2017010836A (es
Inventor
Andreas Schneeweiss
Barbara Burwinkel
Rongxi Yang
Original Assignee
Univ Heidelberg Ruprecht Karls
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Heidelberg Ruprecht Karls filed Critical Univ Heidelberg Ruprecht Karls
Publication of MX2017010836A publication Critical patent/MX2017010836A/es
Publication of MX386750B publication Critical patent/MX386750B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La presente invención se refiere a un método para diagnosticar cáncer de mama en un sujeto, caracterizado porque comprende a) determinar el estado de metilación de al menos un marcador de metilación seleccionado del grupo que consiste en HYAL2, MGRN1, RPTOR, SLC22A18, FUT7, RAPSN, S100P y DYRK4, y b) determinar la cantidad de los marcadores de miARN miR-652, miR-801, miR-376 c, miR376a, miR.127, miR-409 y miR.148b, en un sujeto, en donde el estado de metilación disminuido de al menos un marcador de metilación y la presencia de los miARNs es indicativo del riesgo del sujeto de padecer cáncer de mana.
MX2017010836A 2015-02-24 2016-02-24 MARCADORES DE METILACIÓN Y DE miARN PARA LA DETECCIÓN DE CÁNCER. MX386750B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15156389 2015-02-24
PCT/EP2016/053813 WO2016135168A1 (en) 2015-02-24 2016-02-24 Biomarker panel for the detection of cancer

Publications (2)

Publication Number Publication Date
MX2017010836A MX2017010836A (es) 2018-02-09
MX386750B true MX386750B (es) 2025-03-19

Family

ID=52589264

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010836A MX386750B (es) 2015-02-24 2016-02-24 MARCADORES DE METILACIÓN Y DE miARN PARA LA DETECCIÓN DE CÁNCER.

Country Status (16)

Country Link
US (1) US10941451B2 (es)
EP (1) EP3262190B1 (es)
JP (2) JP6807873B2 (es)
KR (1) KR20170120124A (es)
CN (1) CN107406880A (es)
AU (1) AU2016223532B2 (es)
CA (1) CA2975952C (es)
DK (1) DK3262190T3 (es)
EA (1) EA037995B1 (es)
ES (1) ES2893297T3 (es)
HK (1) HK1246828A1 (es)
IL (1) IL253756B (es)
MX (1) MX386750B (es)
PL (1) PL3262190T3 (es)
UA (1) UA124612C2 (es)
WO (1) WO2016135168A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102100557B1 (ko) * 2017-06-21 2020-04-14 사회복지법인 삼성생명공익재단 대장암 환자의 항암제 치료 반응성 예측용 마커
WO2018236065A1 (ko) * 2017-06-21 2018-12-27 사회복지법인 삼성생명공익재단 대장암 환자의 항암제 치료 반응성 예측용 마커
JP6614630B2 (ja) * 2017-08-23 2019-12-04 国立研究開発法人国立がん研究センター 肝細胞癌のリスク評価方法
WO2019081507A1 (en) 2017-10-23 2019-05-02 Universität Heidelberg NEW MARKERS DERIVED FROM BLOOD FOR CANCER DETECTION
JP7326764B2 (ja) * 2018-03-09 2023-08-16 東ソー株式会社 腫瘍マーカーならびに腫瘍細胞を夾雑細胞と区別して回収および検出する方法
EP3927849A1 (en) * 2019-02-21 2021-12-29 Universität Heidelberg Biomarker panel for diagnosis and prognosis of cancer
GB201906199D0 (en) * 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
CN110136776B (zh) * 2019-05-15 2021-04-20 深圳大学 一种从低质量核糖体印迹数据预测基因编码框的方法和系统
CN110269869B (zh) * 2019-07-30 2023-03-31 宁夏医科大学 一种以蜥蜴为主的抗肿瘤药物及验证方法
CN112176419B (zh) * 2019-10-16 2022-03-22 中国医学科学院肿瘤医院 一种检测ctDNA中肿瘤特异基因的变异和甲基化的方法
CN113186279B (zh) * 2020-01-14 2024-07-02 腾辰生物科技(上海)有限公司 用于辅助诊断癌症的透明质酸酶甲基化标志物及试剂盒
CN113122630B (zh) * 2020-01-15 2024-04-30 腾辰生物科技(上海)有限公司 一种用于辅助诊断癌症的钙结合蛋白甲基化标志物
CN118360405A (zh) * 2020-01-19 2024-07-19 腾辰生物科技(上海)有限公司 一种甲基化标志物在辅助诊断食管癌中的应用
CN113215250B (zh) * 2020-02-04 2024-04-30 腾辰生物科技(上海)有限公司 一个基因的甲基化水平在辅助诊断癌症中的应用
CN113215251B (zh) * 2020-02-04 2024-04-26 腾辰生物科技(上海)有限公司 一种辅助诊断癌症的甲基化标志物
CN113528635B (zh) * 2020-04-16 2024-06-11 腾辰生物科技(上海)有限公司 一种印记基因的甲基化作为心脑血管疾病早期诊断的标志物
WO2022015532A1 (en) * 2020-07-13 2022-01-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for detecting gene fusions of rad51ap1 and dyrk4 and for diagnosing and treating cancer
CN114480630B (zh) * 2020-10-26 2024-09-06 腾辰生物科技(上海)有限公司 用于辅助诊断癌症的一种甲基化标志物
WO2022170133A1 (en) * 2021-02-04 2022-08-11 The Cleveland Clinic Foundation Micro rna liver cancer markers and uses thereof
CN115341027B (zh) * 2021-05-13 2025-08-26 高飞 急性淋巴细胞白血病dna甲基化标志物及其应用
JP7143480B1 (ja) * 2021-06-10 2022-09-28 株式会社大一商会 遊技機
CN114875131A (zh) * 2022-04-24 2022-08-09 上海市东方医院（同济大学附属东方医院） 靶向膜蛋白甲基化作为印记基因综合征标志物的检测方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211606A1 (en) * 2002-05-10 2003-11-13 Isis Pharmaceuticals Inc. Antisense modulation of DYRK4 expression
JP2007531494A (ja) * 2003-07-03 2007-11-08 ジェントロン リミテッド ライアビリティー カンパニー Ｃｎｓ試料において非中枢神経系（ｃｎｓ）疾病を診断するための方法およびシステム
KR20130018438A (ko) * 2004-02-20 2013-02-22 더 리전츠 오브 더 유니버시티 오브 캘리포니아 타액 ｍＲＮＡ 프로파일링, 바이오마커 및 관련 방법 및 부품 키트
EP2129796B1 (en) 2007-02-21 2013-10-23 Oslo Universitetssykehus HF New markers for cancer
WO2009067655A2 (en) * 2007-11-21 2009-05-28 University Of Florida Research Foundation, Inc. Methods of feature selection through local learning; breast and prostate cancer prognostic markers
CN101245386A (zh) 2008-03-26 2008-08-20 中南大学 用于多种肿瘤抑瘤基因检测的cDNA芯片
BRPI0921043A2 (pt) * 2008-11-12 2018-08-07 Caris Life Sciences Luxembourg Holdings métodos e sistemas para usar exossomas para determinar fenótipos
JP2011097833A (ja) * 2009-11-04 2011-05-19 Takeshi Zama 特定の遺伝子のメチル化の頻度を、頭頸部腫瘍のバイオマーカーとして使用する方法
JPWO2011105570A1 (ja) 2010-02-26 2013-06-20 シスメックス株式会社 生体試料中の癌細胞の存否を判定する方法、判定用分子マーカーおよびキット
EP2721179A4 (en) 2011-06-16 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L BIOMARKER COMPOSITIONS AND ASSOCIATED METHODS
JP2013027387A (ja) 2011-06-21 2013-02-07 Tohoku Univ 膵臓癌バイオマーカー
WO2012175562A2 (en) * 2011-06-21 2012-12-27 University Of Tartu Methylation and microrna markers of early-stage non-small cell lung cancer
WO2013190091A1 (en) 2012-06-21 2013-12-27 Ruprecht-Karls-Universität Heidelberg CIRCULATING miRNAs AS MARKERS FOR BREAST CANCER
EP2682477A1 (en) * 2012-07-06 2014-01-08 National University of Ireland, Galway miR-181a and miR652 as oncologic biomarker of breast cancer
WO2014020048A1 (en) * 2012-07-31 2014-02-06 Ruprecht-Karls-Universität Heidelberg Hyal2 methylation and expression as a cancer marker
JP2014036637A (ja) * 2012-08-20 2014-02-27 Hitachi Chemical Co Ltd 癌の切除手術後の予後を判定するためのデータ分析方法

Also Published As

Publication number Publication date
IL253756B (en) 2021-04-29
EP3262190A1 (en) 2018-01-03
JP2018509934A (ja) 2018-04-12
CN107406880A (zh) 2017-11-28
JP6807873B2 (ja) 2021-01-13
HK1246828A1 (zh) 2018-09-14
EA037995B1 (ru) 2021-06-21
UA124612C2 (uk) 2021-10-20
AU2016223532B2 (en) 2021-07-01
KR20170120124A (ko) 2017-10-30
CA2975952A1 (en) 2016-09-01
MX2017010836A (es) 2018-02-09
EA201791578A1 (ru) 2018-02-28
ES2893297T3 (es) 2022-02-08
WO2016135168A1 (en) 2016-09-01
DK3262190T3 (da) 2021-10-11
IL253756A0 (en) 2017-09-28
JP2021052777A (ja) 2021-04-08
CA2975952C (en) 2025-02-06
BR112017018008A2 (pt) 2018-04-10
US20180245159A1 (en) 2018-08-30
PL3262190T3 (pl) 2021-12-20
US10941451B2 (en) 2021-03-09
AU2016223532A1 (en) 2017-08-17
EP3262190B1 (en) 2021-09-01

Similar Documents

Publication Publication Date Title
MX386750B (es) MARCADORES DE METILACIÓN Y DE miARN PARA LA DETECCIÓN DE CÁNCER.
MX394474B (es) Métodos de pronóstico para cáncer de vejiga sin invasión muscular y antagonistas para usarse en el tratamiento de lo mismo.
BR112016029634A2 (pt) kit, dispositivo e método para a detecção de câncer de fígado
BR112016027475A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático
LT3425055T (lt) Molekulinis naviko aptikimo/diagnostikos reagentas
BR112016028944A2 (pt) kit ou dispositivo para a detecção de câncer do trato biliar e método de detecção
MX390764B (es) Ensayos dispersables en agua
CL2017002604A1 (es) Sondas duales silenciadoras
GB2515983A (en) Methods and compositions for providing a preeclampsia assessment
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
MX370850B (es) Marcadores metilados para cancer colorrectal.
MX2017005888A (es) Dispositivos, sistemas y metodos para la deteccion de analitos.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
EP2941267A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF NAFLD, HEPATIC STEATOSIS AND FOLLOWS
BR112017005252A2 (pt) método para detecção de molécula alvo e kit para utilização no referido método.
EP3681504A4 (en) METHOD OF DETECTION USING X-RAY FLUORESCENCE
WO2015197874A3 (en) Combination of cd95/cd95l inhibition and cancer immunotherapy
BR112016018099A2 (pt) Compostos funcionalizados de benzopiranos e uso dos mesmos
IL269315A (en) Detection, quantification and/or isolation of circulating tumor cells based on the expression of cd321 marker
PT3668999T (pt) Métodos e kits para deteção de moléculas de ácido nucleico
MA40636A (fr) Procédés pour détecter le cancer de la prostate
EP3413906A4 (en) COMBINATION COMPOSITIONS FOR CANCER TREATMENT, METHOD AND USES
MX2017013729A (es) Deteccion especifica de isoformas de clusterina.
BR112015020054A2 (pt) Método de detectar resistência aos efeitos terapêuticos de um inibidor de akt em uma célula cancerosa
EP3111223C0 (en) LUNG CANCER BIOMARKERS, METHODS AND KITS THEREOF